Inclusion Criteria:

• Patients must have histologically confirmed advanced, prostate cancer
• Patients must have evaluable disease that may be evaluated by PSA or measurement.
• Patients must be hormone refractory as defined in this protocol.
• Patients must be taxane refractory as defined in this protocol.
• Patients have had no prior chemotherapy other than a taxane or estramustine phosphate.
• Patients may have had prior radiation therapy (RT) if it has been >/= 4 weeks since completion.
• Patients on bisphosphonates may be included.
• Patients must be at least 18 years of age or older.
• Patients must have the ability to speak and understand English.
• Patients must have an ECOG performance status of 2 or less.
• Patients must have adequate bone marrow function: platelets > 100,000 cells/mm3; hemoglobin > 9.0 g/dL; and absolute neutrophil count (ANC) > 1,000 cells/mm3.
• Patients must have adequate renal function: creatinine < 2.5 mg/dL.
• Patients must have adequate liver function.
• Ejection fraction of > 50% within 42 days of first dose of study drug.
• Ability to complete the McGill-Melzack Pain Intensity Scale.

Exclusion Criteria:

• Patients with unstable medical conditions such as liver, renal dysfunctions, blood clots or heart disease.
• History of hypersensitivity to doxorubicin.
• History of class II cardiac disease or evidence of congestive heart failure.
• RT within the past 4 weeks of study entry or a radiopharmaceutical within the past 8 weeks of study entry.
• Prior malignancy within the past 5 years except for non-melanotic skin cancers.